There are a ton of small start ups trying to do this, and they’ve been at it for a decade. At best they will be able to screen for the least toxic drug candidates in specific tissue types, which will then have to be tested in clinical trials. Could be very helpful, but not a surrogate for clinical testing.
The article only claims a 30%-50% improvement in drug development time.
I like the idea because it makes smaller drug companies more competitive.
The technology will also have an impact on re-purposing approved drugs, treatments for uncommon diseases, and identifying environmental toxins.